1. Cancer survivorship: The concept and the increasingly recognized reality

   • Maurie Markman

   Editor’s Commentary Pages: 79 - 80

2. Web alert

   News Pages: 81 - 82

3. VEGF-targeted therapy in renal cell carcinoma: Active drugs and active choices

   • Brian I. Rini

   OriginalPaper Pages: 85 - 89

4. Her-2 targeted therapy: Beyond breast cancer and trastuzumab

   • Keith T. Flaherty
   • Marcia S. Brose

   OriginalPaper Pages: 90 - 95

5. Integrins: Molecular targets in cancer therapy

   • Gordon C. Tucker

   OriginalPaper Pages: 96 - 103

6. Phenoxodiol: Isoflavone analog with antineoplastic activity

   • Toni K. Choueiri
   • Robert Wesolowski
   • Tarek M. Mekhail

   OriginalPaper Pages: 104 - 107

7. Endothelin receptor antagonists: Rationale, clinical development, and role in prostate cancer therapeutics

   • Snehal G. Thakkar
   • Toni K. Choueiri
   • Jorge A. Garcia

   OriginalPaper Pages: 108 - 113

8. Interleukins 18 and 21: Biology, mechanisms of action toxicity, and clinical activity

   • Theodore F. Logan
   • Michael J. Robertson

   OriginalPaper Pages: 114 - 119

9. Comorbidity in patients with cancer of the head and neck: Prevalence and impact on treatment and prognosis

   • Jay F. Piccirillo
   • Anna Vlahiotis

   OriginalPaper Pages: 123 - 129

10. The role of human papillomavirus in squamous carcinoma of the head and neck

    • Guojun Li
    • Erich M. Sturgis

    OriginalPaper Pages: 130 - 139

11. How to reduce radiation-related toxicity in patients with cancer of the head and neck

    • Adam S. Garden
    • Jan S. Lewin
    • Mark S. Chambers

    OriginalPaper Pages: 140 - 145

12. Oral premalignancy: New methods of detection and treatment

    • Ann Gillenwater
    • Vali Papadimitrakopoulou
    • Rebecca Richards-Kortum

    OriginalPaper Pages: 146 - 154